Cingulate Inc. CING
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +14.75%
- 1 year
- +37.95%
- Open
- 5.04
- Prev close
- 5.19
- Mkt cap
- 72.42M
- Vol
- 76.66K
- Avg vol
- 121.58K
- EPS
- -3.51
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.84
- High
- 5.10
- Forward P/E
- -0.65
- Beta
- 0.00
- Short ratio
- 0.69
- Inst. own
- 1.56%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 4.27
- 200-d avg
- 7.16
- 1y target
- 48.33
5D chart
Signals (77)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:55 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:40 PM | 1 day ago |
| SMA: Bearish | Oct 30, 3:30 PM | 1 day ago |
| MACD: Buy Signal | Oct 30, 3:25 PM | 1 day ago |
| SMA: Bullish | Oct 30, 3:20 PM | 1 day ago |
| MACD: Sell Signal | Oct 30, 2:05 PM | 1 day ago |
| SMA: Bearish | Oct 30, 12:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 10:50 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:35 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:15 AM | 2 days ago |
| RSI: Oversold | Oct 30, 10:00 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 9:30 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 9:30 AM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 3:55 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:55 PM | 2 days ago |
| MACD: Sell Signal | Oct 29, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 2 days ago |
| SMA: Bearish | Oct 29, 3:35 PM | 2 days ago |
| MACD: Buy Signal | Oct 29, 3:00 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 2 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 2 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:45 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:25 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 9:45 AM | 3 days ago |
| MACD: Buy Signal | Oct 28, 3:50 PM | 3 days ago |
| SMA: Bullish | Oct 28, 3:45 PM | 3 days ago |
| MACD: Sell Signal | Oct 28, 3:30 PM | 3 days ago |
| SMA: Bearish | Oct 28, 3:10 PM | 3 days ago |
| SMA: Bullish | Oct 28, 1:15 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:55 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:25 PM | 4 days ago |
| RSI: Oversold | Oct 28, 12:10 PM | 4 days ago |
| RSI: Oversold | Oct 28, 11:45 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 11:35 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:45 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:45 PM | 4 days ago |
| MACD: Sell Signal | Oct 27, 3:45 PM | 4 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 4 days ago |
| SMA: Bearish | Oct 27, 3:10 PM | 4 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 4 days ago |
| MACD: Buy Signal | Oct 27, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 27, 1:25 PM | 4 days ago |
| SMA: Bearish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:15 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 11:10 AM | 5 days ago |
| RSI: Overbought | Oct 27, 10:15 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:40 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 26, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 26, 2:50 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:45 PM | 5 days ago |
| SMA: Bullish | Oct 26, 2:45 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 5 days ago |
| SMA: Bearish | Oct 26, 2:10 PM | 5 days ago |
| SMA: Bullish | Oct 26, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 26, 1:10 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:40 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:15 AM | 6 days ago |
News
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares rose 93.3% to $2.03 during Tuesday's pre-market session. The company's market cap stands at $2.6 million. Scinai Immunotherapeutics (NASDAQ:SCNI)…
1 month ago globenewswire.com
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma Chief Commercial Officer Bryan Downey Joins Panel Discussion on…
-
2 months ago benzinga.com
Roth Capital Reiterates Buy on Cingulate, Lowers Price Target to $9
Roth Capital analyst Boobalan Pachaiyappan reiterates Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $10 to $9.
-
2 months ago benzinga.com
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $44
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $52 to $44.
-
2 months ago benzinga.com
Cingulate Q2 EPS $(0.45) Beats $(0.63) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.63) by 28.57 percent. This is a 60.53 percent increase over losses of $(1.14)…
2 months ago globenewswire.com
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to…
2 months ago globenewswire.com
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301's Differentiated Pharmacokinetic Profile
KANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision…
3 months ago globenewswire.com
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology Publication helps establish the…
-
4 months ago benzinga.com
Cingulate Joins Russell 3000E Index
Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of…
4 months ago globenewswire.com
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility…
4 months ago globenewswire.com
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform…
4 months ago benzinga.com
Apple To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts change outlook on top names. B of A cuts CPB, UBS cuts AJG PT, B of A boosts ORCL PT, Needham raises APLD PT, Morgan Stanley raises AAPL PT, BTIG raises NRIX PT, GLJ Research…
4 months ago benzinga.com
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
-
4 months ago benzinga.com
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $52
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $55 to $52.
4 months ago newsfilecorp.com
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
Dallas, Texas--(Newsfile Corp. - June 4, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's latest update shifts the…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
5 months ago reuters.com
US FDA declines to approve Cingulate's ADHD drug
Cingulate said on Tuesday that the U.S. Food and Drug Administration declined to approve its drug to treat attention deficit hyperactivity disorder.
-
5 months ago benzinga.com
Cingulate Receives FDA Complete Response Letter For ADHD Treatment CTx-1301 Requesting Specific Information About Chemistry, Manufacturing, And Controls, Contains No Concerns Regarding Safety Or Efficacy
The response identified specific Chemistry, Manufacturing and Controls (CMC) information requests and did not raise any current concerns regarding the clinical safety or efficacy of CTx-1301.…
5 months ago globenewswire.com
Cingulate Receives Complete Response Letter from FDA for CTx-1301
No Clinical Safety or Efficacy Concerns Currently Identified Agency Feedback Primarily Focused on CMC-Related Requests Company Plans Prompt Response and Submission of Requested Information Company is…
-
5 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Cingulate, Maintains $20 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Cingulate (NASDAQ:CING) with a Buy and maintains $20 price target.
-
5 months ago benzinga.com
Cingulate Q1 EPS $(0.95) Misses $(0.53) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.53) by 79.25 percent. This is a 10.38 percent increase over losses of $(1.06)…
5 months ago globenewswire.com
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to…
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
6 months ago benzinga.com
Amazon To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts changed outlook on top names. See all changes on Benzinga's analyst ratings page. Price targets and ratings altered for CING, WING, DEFT, FANG, PJT, DOCS, and AMZN.
-
6 months ago benzinga.com
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $55
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $58 to $55.
6 months ago newsfilecorp.com
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues…
-
7 months ago benzinga.com
Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $14
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $16 to $14.
7 months ago benzinga.com
What's Going On With Cingulate Stock Today?
Cingulate slipped in premarket trading as investors weighed its wider quarterly loss against a fresh patent win and new funding to support its ADHD drug launch plans.
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
Cingulate Q4 EPS $(0.84) Misses $(0.61) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.61) by 37.03 percent. This is a 500 percent decrease over losses of $(0.14)…
7 months ago invezz.com
Why did Cingulate stock skyrocket today?
Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release…
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
10 months ago defenseworld.net
Cingulate Inc. (NASDAQ:CING) Given Consensus Recommendation of “Moderate Buy” by Analysts
Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have earned a consensus rating of "Moderate Buy" from the five research firms that are covering the firm, Marketbeat.com reports. One…
10 months ago defenseworld.net
Cingulate Inc. (NASDAQ:CING) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Shares of Cingulate Inc. (NASDAQ: CING - Get Free Report) have been assigned an average rating of "Moderate Buy" from the five ratings firms that are currently covering the firm, Marketbeat reports.…
-
10 months ago benzinga.com
Cingulate CEO Shane Schaffer Reinstated Following Legal Matter; Mr. Roberts To No Longer Serve As Executive Chairman Of The Board But Will Continue To Serve As Chairman
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed on August 14, 2025, the…
-
10 months ago benzinga.com
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $58
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $62 to $58.
-
11 months ago benzinga.com
Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $16
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $17 to $16.
11 months ago newsfilecorp.com
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results…
-
1 year ago benzinga.com
Cingulate Releases Phase 3 Trial Results For Its ADHD Treatment CTX-1301 Showing The Drug Met Its Primary Endpoints, Showing Dose-Dependent Improvements On ADHD Symptom And Severity Scales, And Demonstrated Effective Once-Daily Symptom Relief Using The Company's Precision Timed Release Technology
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
-
1 year ago benzinga.com
Cingulate's Data From Lead ADHD Candidate CTx-1301 Selected For Podium Presentation At AACAP Annual Meeting In Chicago
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
1 year ago globenewswire.com
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to…
-
1 year ago benzinga.com
Roth Capital Maintains Buy on Cingulate, Raises Price Target to $17
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $10 to $17.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
Cingulate Announces That U.S. FDA Accepts For Review Its New Drug Application For CTx-1301, Its Lead ADHD Treatment Candidate For Children And Adults
Cingulate Inc. (NASDAQ:CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
-
1 year ago benzinga.com
Cingulate Enters Commercial Supply Agreement With Bend Bio Sciences For Manufacturing Of CTx-1301, Its Lead Drug Candidate For Treating ADHD
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation
1 year ago globenewswire.com
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval
-
1 year ago benzinga.com
Ascendiant Capital Maintains Buy on Cingulate, Raises Price Target to $62
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $61 to $62.
1 year ago newsfilecorp.com
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate reported 2Q25 results…
-
1 year ago benzinga.com
Cingulate Q2 EPS $(1.09) Misses $(0.84) Estimate
Cingulate (NASDAQ:CING) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.84) by 29.3 percent. This is a 80.07 percent increase over losses of $(5.47)…